These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9272371)

  • 1. Public health application of acellular pertussis vaccines.
    Hadler SC; Orenstein WA
    Dev Biol Stand; 1997; 89():355-61. PubMed ID: 9272371
    [No Abstract]   [Full Text] [Related]  

  • 2. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acellular pertussis vaccines: the next step.
    Halperin SA
    Dev Biol Stand; 1997; 89():363-5. PubMed ID: 9272372
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Dylag AM; Shah SI
    Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of pertussis and use of acellular pertussis vaccines in Japan.
    Kuno-Sakai H; Kimura M
    Dev Biol Stand; 1997; 89():331-2. PubMed ID: 9272368
    [No Abstract]   [Full Text] [Related]  

  • 7. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public health implications: United Kingdom.
    Miller E
    Dev Biol Stand; 1997; 89():367-8. PubMed ID: 9272373
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy trial of acellular pertussis vaccines; trial I.
    Olin P
    Dev Biol Stand; 1997; 89():52-4. PubMed ID: 9333569
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers.
    Greer AL; Fisman DN
    Pediatrics; 2011 Sep; 128(3):e591-9. PubMed ID: 21844056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis.
    Wilson TR
    J Pediatr Health Care; 2006; 20(4):229-37. PubMed ID: 16831630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Japanese experience with 60 million doses of acellular pertussis vaccines.
    Sato H
    Dev Biol Stand; 1997; 89():327-9. PubMed ID: 9272367
    [No Abstract]   [Full Text] [Related]  

  • 13. [[Health and economic benefits of mandatory regular vaccination in the Slovak Republic. III. Diphtheria, tetanus and pertussis] ].
    Hudecková H; Straka S; Szilágyiová M; Rusnáková S
    Epidemiol Mikrobiol Imunol; 2000 Nov; 49(4):153-7. PubMed ID: 11188762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.
    Gidengil CA; Sandora TJ; Lee GM
    Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Gothenburg pertussis vaccine study.
    Trollfors B; Taranger J
    Dev Biol Stand; 1997; 89():49-51. PubMed ID: 9333568
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of a three-component acellular pertussis vaccine (DTaP) in early childhood after household exposure to "typical" (WHO-defined) pertussis.
    Schmitt HJ
    Dev Biol Stand; 1997; 89():67-9. PubMed ID: 9333573
    [No Abstract]   [Full Text] [Related]  

  • 17. Case-control study to evaluate the efficacy of the BIKEN acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP) in infants.
    Beloradsky BH
    Dev Biol Stand; 1997; 89():70-3. PubMed ID: 9333574
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety of acellular pertussis vaccine: follow-up studies.
    Chen RT
    Dev Biol Stand; 1997; 89():373-5. PubMed ID: 9272374
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.
    Iskedjian M; Walker JH; Hemels ME
    Vaccine; 2004 Oct; 22(31-32):4215-27. PubMed ID: 15474711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.